osapiens | $100,000,000 | (Jan 15, 2026)
Musical AI | $4,500,000 | (Jan 15, 2026)
Harmattan AI | $200,000,000 | (Jan 15, 2026)
Iktos
France
- Paris
- 10/03/2023
- Series A
- $16,428,000
We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization.
Our de novo design algorithm is based on deep generative models with reinforcement learning. It designs novel and easy to make compounds, optimized to meet a given multi-objective blueprint, with unprecedented speed, performance, and diversity.
Please visit our webpage to know more about our products and offerings
https://iktos.ai/products/
- Industry Biotechnology
- Website https://iktos.ai/
- LinkedIn https://www.linkedin.com/company/iktos/
Related People
Yann Gaston-MatheFounder
France -
Greater Paris Metropolitan Region
I am a senior Life Science professional with extensive experience in Pharma R&D and Data Analytics for Life Science and Healthcare. I am an entrepreneur at heart, I have started several biotech companies, and I am the co-founder and CEO of Iktos, a start-up company specialising in artificial intelligence technology for chemical optimization in drug discovery.
Aikido Security | $60,000,000 | (Jan 15, 2026)
Tive | $20,000,000 | (Jan 15, 2026)
IO River | $20,000,000 | (Jan 15, 2026)
Flip (US) | $20,000,000 | (Jan 15, 2026)
MeetCaria | $1,000,000 | (Jan 15, 2026)
SkyFi | $12,700,000 | (Jan 15, 2026)
Axol Bioscience Ltd. | $28,000,000 | (Jan 15, 2026)
Titl | $2,500,000 | (Jan 15, 2026)
bricks.sh | $1,863,303 | (Jan 14, 2026)